US 11,865,151 B2
Live biotherapeutics for the treatment of carbohydrate disorders
Genevieve Hansen, Rancho Santa Fe, CA (US)
Filed by GUTSYBIO INC., San Diego, CA (US)
Filed on Feb. 14, 2020, as Appl. No. 16/792,178.
Claims priority of provisional application 62/972,451, filed on Feb. 10, 2020.
Claims priority of provisional application 62/805,922, filed on Feb. 14, 2019.
Prior Publication US 2020/0261521 A1, Aug. 20, 2020
Int. Cl. A61K 36/06 (2006.01); C12N 1/16 (2006.01); A23L 33/14 (2016.01); A23L 33/00 (2016.01); A23L 33/21 (2016.01)
CPC A61K 36/06 (2013.01) [A23L 33/14 (2016.08); A23L 33/21 (2016.08); A23L 33/30 (2016.08); C12N 1/16 (2013.01); A23V 2002/00 (2013.01)] 7 Claims
OG exemplary drawing
 
1. A method for treating galactosemia or dietary intolerance of galactose, in a subject, comprising:
administering to the subject with galactosemia or dietary intolerance of galactose an effective amount of an adaptively evolved microorganism to the subject wherein the effective amount of the adaptively evolved microorganism reduces the amount of the galactose in the presence of glucose.